Pulmatrix Stock Working Capital
| PULM Stock | USD 6.12 0.01 0.16% |
Pulmatrix fundamentals help investors to digest information that contributes to Pulmatrix's financial success or failures. It also enables traders to predict the movement of Pulmatrix Stock. The fundamental analysis module provides a way to measure Pulmatrix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pulmatrix stock.
Pulmatrix |
Pulmatrix Company Working Capital Analysis
Pulmatrix's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Pulmatrix Working Capital | 16.93 M |
Most of Pulmatrix's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pulmatrix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Based on the company's disclosures, Pulmatrix has a Working Capital of 16.93 M. This is 96.02% lower than that of the Pharmaceuticals sector and 96.86% lower than that of the Health Care industry. The working capital for all United States stocks is 98.85% higher than that of the company.
Pulmatrix Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pulmatrix's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pulmatrix could also be used in its relative valuation, which is a method of valuing Pulmatrix by comparing valuation metrics of similar companies.Pulmatrix is currently under evaluation in working capital category among its peers.
Pulmatrix Fundamentals
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (0.95) % | ||||
| Operating Margin | (3.80) % | ||||
| Current Valuation | 11.53 M | ||||
| Shares Outstanding | 3.65 M | ||||
| Shares Owned By Institutions | 7.16 % | ||||
| Number Of Shares Shorted | 7.05 K | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 2.04 X | ||||
| Price To Sales | 1.96 X | ||||
| Revenue | 7.3 M | ||||
| Gross Profit | 6.07 M | ||||
| EBITDA | (12.65 M) | ||||
| Net Income | (14.12 M) | ||||
| Cash And Equivalents | 42.91 M | ||||
| Cash Per Share | 12.67 X | ||||
| Total Debt | 8.76 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.19 X | ||||
| Book Value Per Share | 4.93 X | ||||
| Cash Flow From Operations | (15.98 M) | ||||
| Short Ratio | 0.75 X | ||||
| Earnings Per Share | (2.64) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 22 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 22.32 M | ||||
| Total Asset | 33.96 M | ||||
| Retained Earnings | (287.6 M) | ||||
| Working Capital | 16.93 M | ||||
| Current Asset | 8.34 M | ||||
| Current Liabilities | 4.11 M | ||||
| Net Asset | 33.96 M |
About Pulmatrix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pulmatrix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pulmatrix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pulmatrix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Pulmatrix Piotroski F Score and Pulmatrix Altman Z Score analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.